Company
Vanda Pharmaceuticals
Vanda Pharmaceuticals has 15 drugs tracked on RxWires: 1 post-market, 7 in Phase 3, 4 in Phase 2, 1 in Phase 1/2, 2 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Iloperidone | Post-Market | Schizophrenia |
| Tradipitant | Phase 3 | Motion Sickness |
| Ponesimod | Phase 3 | Ulcerative Colitis (UC) |
| tasimelteon | Phase 3 | Non 24 Hour Sleep Wake Disorder |
| Double-blind 200 mg imsidolimab | Phase 3 | Generalized Pustular Psoriasis |
| VQW-765 | Phase 3 | Social Anxiety Disorder (SAD) |
| 750 mg Imsidolimab | Phase 3 | Generalized Pustular Psoriasis |
| Milsaperidone | Phase 3 | Major Depressive Disorder (MDD) |
| VSF-173 | Phase 2 | Excessive Somnolence |
| VLY-686 | Phase 2 | Treatment-resistant Pruritus Associated With Atopic Dermatitis |
| Trichostatin A | Phase 2 | Onychomycosis of Toenail |
| VEC-162 | Phase 2 | Circadian Rhythm Sleep Disorders |
| VCA-894A | Phase 1/2 | Charcot Marie Tooth Disease (CMT) |
| VHX-896 and iloperidone | Phase 1 | Healthy |
| VHX-896 | Phase 1 | Healthy |
Latest
- Iloperidone moved to Post-Market
- vanda pharmaceuticals filed 8-K
- vanda pharmaceuticals filed 8-K
- vanda pharmaceuticals filed 8-K
- vanda pharmaceuticals filed 8-K
Follow Vanda Pharmaceuticals on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.